Zogenix (NASDAQ:ZGNX) Post Smaller Loss in Fiscal Q4; Ends Marketing Partnership – ZGNX, AGN, ENDP, ALKS

The SAN DIEGO, California based Zogenix, Inc (NASDAQ:ZGNX) announced on Friday that it had a smaller loss in fiscal Q4 after it finished a marketing partnership on its injectable migraine treatment, Sumavel DosePro.

Zogenix ended a marketing partnership with Japanese drug manufacturer Astellas Pharma in early 2012, and as a result the company’s selling and general expenses decreased compared to a year ago.

Sumavel DosePro is only approved medicine of the company and it reported sales move up 12% to $9.5 million during fiscal Q4.

Zogenix announced a loss of a penny per share. The medicine company lost $23.7 million or 36 cents a share in fiscal Q4 of previous year.

FactSet data confirms that Analysts’ predicts a loss of 16 cents a share and revenue of $9.9 million.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Allergan, Inc. (NYSE:AGN) fell -0.34% to settle at $108.98, Endo Health Solutions Inc (NASDAQ:ENDP) moved down -1.82% to end at $30.68 while Alkermes Plc (NASDAQ:ALKS) plunged -1.81% to finish at $22.75 on Friday.

Zogenix, Inc. (NASDAQ:ZGNX) last session’s volume of 3.30 million shares was surprisingly higher than its average volume of 1.73 million shares. The stock after opening at $2.00 hit high price of $2.12 and then closed at $1.99 by scoring +6.13%.

The liquidity measure in recent quarter results of the company was recorded 1.56 as current ratio and on the other side the debt to equity ratio was 2.14 and long-term debt to equity ratio remained at 2.14. The Company had total cash of $1.28 billion at hand and a book value per share as $2.34 in the most recent quarter.

The stock’s price volatility was 8.35% for a week and 10.66% for a month as well as price volatility’s Average True Range for 14 days was 0.16.

ZGNX generated revenue of $42.73 million in the previous twelve months and earned -$70.45 million. The Company showed a negative -164.86% in the net profit margin as well as in its operating margin which remained at -125.99%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.